Our Commitment
Congruence develops medicines for genetically defined diseases with scientific rigor and urgency. As we advance our first medicine into clinical trials, our mission is inspired by the individuals and families affected by serious diseases with limited treatment options. Our goal is to deliver therapies that better the lives of patients and communities.
Clinical Trials
A phase 1/1b study of CGX-926 for people experiencing genetic obesity with MC4R-deficiency is currently ongoing in the UK. If you have an interest in learning more about this and future trials, please contact us at clinicaltrials@congruencetx.com.
By reaching out to us, you are expressly consenting to the processing of your personal data for the purposes of your communication. Please refer to the Privacy Policy for further information.